Radiopharmaceutical Validation for Clinical Use
Radiopharmaceuticals are reemerging as attractive anticancer agents, but there are no universally adopted guidelines or standardized procedures for evaluating agent validity before early-phase trial implementation. To validate a radiopharmaceutical, it is desirous for the radiopharmaceutical to be s...
Main Authors: | Charles A. Kunos, Rodney Howells, Aman Chauhan, Zin W. Myint, Mark E. Bernard, Riham El Khouli, Jacek Capala |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-03-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.630827/full |
Similar Items
-
Radiopharmaceutical Switch Maintenance for Relapsed Ovarian Carcinoma
by: Charles A. Kunos, et al.
Published: (2020-09-01) -
Radiopharmaceuticals for Relapsed or Refractory Leukemias
by: Charles A. Kunos, et al.
Published: (2019-02-01) -
Activities, procedures and doses in pediatric patients due to radiopharmaceuticals
by: Silvia Maria Velasques de Oliveira, et al.
Published: (2008-12-01) -
EANM guideline on the validation of analytical methods for radiopharmaceuticals
by: Nic Gillings, et al.
Published: (2020-02-01) -
Analysis of Current Rules and Regulations for Preclinical Studies of Radiopharmaceuticals
by: A. S. Lunev, et al.
Published: (2024-02-01)